Immunic, Inc. vs Incyte Corporation — Valuation Comparison 2026
Access all valuation models for IMUX vs INCY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →INCY scores higher with a 6.4/10 quality rating vs IMUX's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Immunic, Inc. (IMUX) and Incyte Corporation (INCY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
IMUX currently trades at $14.97 with a QOC of 4.9/10, while INCY trades at $97.50 with a QOC of 6.4/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).